Statera Biopharma (STAB) Competitors $0.0001 0.00 (0.00%) As of 10/8/2025 01:21 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock STAB vs. VRPX, SCPS, TRVN, ARDS, NAVB, EVLO, GNCAQ, GNCA, CMRA, and SYRSShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Comera Life Sciences (CMRA), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Comera Life Sciences Syros Pharmaceuticals Statera Biopharma (NASDAQ:STAB) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends. Is STAB or VRPX more profitable? Statera Biopharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Statera BiopharmaN/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34%-338.29% Does the media prefer STAB or VRPX? In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score. Company Overall Sentiment Statera Biopharma Neutral Virpax Pharmaceuticals Neutral Which has more volatility & risk, STAB or VRPX? Statera Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Do insiders and institutionals hold more shares of STAB or VRPX? 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, STAB or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStatera BiopharmaN/AN/AN/AN/AN/AVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/A SummaryStatera Biopharma beats Virpax Pharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$1.05B$6.09B$10.54BDividend YieldN/A4.84%5.69%4.71%P/E RatioN/A1.2685.3527.60Price / SalesN/A148.70539.78202.41Price / CashN/A17.6437.9261.55Price / BookN/A7.5213.016.76Net IncomeN/A-$7.77M$3.30B$275.88M7 Day PerformanceN/A26.65%4.34%2.81%1 Month PerformanceN/A27.91%9.49%9.24%1 Year PerformanceN/A-5.66%84.83%35.42% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00flatN/A-50.0%$5KN/A0.0020VRPXVirpax Pharmaceuticals0.061 of 5 stars$0.01+9.9%N/A-99.8%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009TRVNTrevena1.9951 of 5 stars$0.01-20.0%$5.00+41,566.7%-99.2%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00-84.6%N/AN/A$11KN/A0.0030Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/AN/A$10K$8.13K0.0010News CoverageGap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070CMRAComera Life SciencesN/A$0.00flatN/AN/A$3K$1.00M0.002SYRSSyros Pharmaceuticals3.7945 of 5 stars$0.00flat$1.00+999,900.0%-99.8%$3K$386K0.00120 Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Comera Life Sciences Competitors Syros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
